CinCor Pharma, Inc., (CINC): Price and Financial Metrics
CINC Price/Volume Stats
| Current price | $29.06 | 52-week high | $43.15 |
| Prev. close | $29.20 | 52-week low | $10.53 |
| Day low | $29.02 | Volume | 6,349,700 |
| Day high | $29.35 | Avg. volume | 818,447 |
| 50-day MA | $22.81 | Dividend yield | N/A |
| 200-day MA | $24.66 | Market Cap | 1.27B |
CINC Stock Price Chart Interactive Chart >
CinCor Pharma, Inc., (CINC) Company Bio
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension and primary aldosteronism, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Latest CINC News From Around the Web
Below are the latest news stories about CINCOR PHARMA INC that investors may wish to consider to help them evaluate CINC as an investment opportunity.
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of BaxdrostatWALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective aldosterone synthase inhibitor. On February 17, 2023, the Company received the official meeting minutes from the End-of-Phase 2 meeting with the FDA held on |
CinCor CEO: acquisition by AstraZeneca was more than a year in the makingBefore CinCor Pharma Inc. agreed to a $1.8 billion acquisition by AstraZeneca plc, it turned down several other offers from the U.K. pharmaceutical giant. |
Why These Two Biotech Stocks Blasted Higher This WeekTwo somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence. |
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & MoreUpdates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week. |
AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor BuyoutAstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor. |
CINC Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...